{
    "id": "5eb0e4a7-f749-4308-8873-efba1717a0c6",
    "indications": {
        "text": "kevzara \u00ae interleukin-6 ( il-6 ) receptor antagonist indicated treatment : adult patients moderately severely active rheumatoid arthritis ( rheumatoid arthritis ) inadequate response intolerance one disease-modifying antirheumatic drugs ( dmards ) . ( 1.1 ) adult patients polymyalgia rheumatica ( pmr ) inadequate response corticosteroids tolerate corticosteroid taper . ( 1.2 ) patients weigh 63 kg greater active polyarticular juvenile idiopathic arthritis ( pjia ) . ( 1.3 )",
        "doid_entities": [
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "polymyalgia rheumatica (DOID:853)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_853"
            },
            {
                "text": "juvenile idiopathic arthritis (DOID:676)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_676"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "general considerations kevzara initiation recommended patients anc less 2,000/mm 3 , platelets less 150,000/mm 3 liver transaminases 1.5 times uln . full prescribing information ( fpi ) complete information . ( 2.1 ) recommended rheumatoid arthritis recommended 200 mg subcutaneously , every 2 weeks . ( 2.2 ) rheumatoid arthritis , kevzara may used monotherapy combination methotrexate ( mtx ) conventional dmards . ( 2.2 ) recommended pmr recommended 200 mg subcutaneously , every two weeks combination tapering course corticosteroids . ( 2.3 ) pmr , kevzara used monotherapy following discontinuation corticosteroids . ( 2.3 ) recommended pjia recommended 200 mg given subcutaneously every 2 weeks pjia patients weigh 63 kg greater using 200 mg/1.14 ml pre-filled syringe . ( 2.4 ) pjia , kevzara used monotherapy combination conventional dmards . ( 2.4 ) modifications cytopenias , abnormal liver enzymes , infections fpi complete information . ( 2.6 )",
        "doid_entities": [
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "kevzara ( sarilumab ) injection supplied clear colorless pale yellow solution single-dose pre-filled syringes , single-dose pre-filled pens . strength package size ndc number 150 mg/1.14 ml 2 syringes per pack 0024-5908-01 200 mg/1.14 ml 2 syringes per pack 0024-5910-01 strength package size ndc number 150 mg/1.14 ml 2 pre-filled pens per pack 0024-5920-01 200 mg/1.14 ml 2 pre-filled pens per pack 0024-5922-01",
    "adverseReactions": "kevzara contraindicated patients known hypersensitivity sarilumab inactive ingredients [ ( 5.5 ) ( 6.1 ) ] .",
    "ingredients": [
        {
            "name": "SARILUMAB",
            "code": "NU90V55F8I",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11767"
        },
        {
            "name": "ARGININE",
            "code": "94ZLA3W45F",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29016"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_27570"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53424"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "organization": "Sanofi-Aventis U.S. LLC",
    "name": "KEVZARA",
    "effectiveTime": "20250516",
    "indications_original": "KEVZARA \u00ae is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). ( 1.1 ) adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. ( 1.2 ) patients who weigh 63 kg or greater with active polyarticular juvenile idiopathic arthritis (pJIA). ( 1.3 )",
    "contraindications_original": "General Considerations for Administration KEVZARA initiation is not recommended in patients with ANC less than 2,000/mm 3 , platelets less than 150,000/mm 3 or liver transaminases above 1.5 times ULN. See Full Prescribing Information (FPI) for complete information. ( 2.1 ) Recommended Dosage in RA The recommended dosage is 200 mg subcutaneously, once every 2 weeks. ( 2.2 ) For RA, KEVZARA may be used as monotherapy or in combination with methotrexate (MTX) or other conventional DMARDs. ( 2.2 ) Recommended Dosage in PMR The recommended dosage is 200 mg subcutaneously, once every two weeks   in combination with a tapering course of corticosteroids. ( 2.3 ) For PMR, KEVZARA can be used as monotherapy following discontinuation of corticosteroids. ( 2.3 ) Recommended Dosage in pJIA The recommended dosage is 200 mg given subcutaneously once every 2 weeks for pJIA patients who weigh 63 kg or greater using the 200 mg/1.14 mL pre-filled syringe. ( 2.4 ) For pJIA, KEVZARA can be used as monotherapy or in combination with conventional DMARDs. ( 2.4 ) Dosage Modifications for Cytopenias, Abnormal Liver Enzymes, Infections See FPI for complete information. ( 2.6 )",
    "warningsAndPrecautions_original": "KEVZARA (sarilumab) injection is supplied as a clear and colorless to pale yellow solution in single-dose pre-filled syringes, and single-dose pre-filled pens.\n                  \n                     \n                     \n                     \n                     \n                        \n                           Strength\n                           Package Size\n                           NDC Number\n                        \n                     \n                     \n                        \n                           150 mg/1.14 mL\n                           2 syringes per pack\n                           0024-5908-01\n                        \n                        \n                           200 mg/1.14 mL\n                           2 syringes per pack\n                           0024-5910-01\n                        \n                     \n                  \n                  \n                     \n                     \n                     \n                     \n                        \n                           Strength\n                           Package Size\n                           NDC Number\n                        \n                     \n                     \n                        \n                           150 mg/1.14 mL\n                           2 pre-filled pens per pack\n                           0024-5920-01\n                        \n                        \n                           200 mg/1.14 mL\n                           2 pre-filled pens per pack\n                           0024-5922-01",
    "adverseReactions_original": "KEVZARA is contraindicated in patients with known hypersensitivity to sarilumab or any of the inactive ingredients [see Warnings and Precautions (5.5) and Adverse Reactions (6.1)].",
    "drug": [
        {
            "name": "KEVZARA",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11767"
        }
    ]
}